168 related articles for article (PubMed ID: 31240558)
1. Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test.
Kondo T; Fujioka M; Fujisawa S; Sato K; Tsuda M; Miyagishima T; Mori A; Iwasaki H; Kakinoki Y; Yamamoto S; Haseyama Y; Ando S; Shindo M; Ota S; Kurosawa M; Ohba Y; Teshima T;
Int J Hematol; 2019 Oct; 110(4):482-489. PubMed ID: 31240558
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment evaluation of fluorescence resonance energy transfer-based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib.
Kondo T; Fujioka M; Tsuda M; Murai K; Yamaguchi K; Miyagishima T; Shindo M; Nagashima T; Wakasa K; Fujimoto N; Yamamoto S; Yonezumi M; Saito S; Sato S; Ogawa K; Chou T; Watanabe R; Kato Y; Takahashi S; Okano Y; Yamamoto J; Ohta M; Iijima H; Oba K; Kishino S; Sakamoto J; Ishida Y; Ohba Y; Teshima T;
Cancer Sci; 2018 Jul; 109(7):2256-2265. PubMed ID: 29719934
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
4. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
[TBL] [Abstract][Full Text] [Related]
5. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
6. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of nilotinib in the first-line treatment of chronic myeloid leukemia and the analysis of factors affecting molecular responses].
Chen LY; Li Z; Zhang Y; Zhou J; Zhao HF; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):477-482. PubMed ID: 32654460
[No Abstract] [Full Text] [Related]
8. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
Giles FJ; Yin OQ; Sallas WM; le Coutre PD; Woodman RC; Ottmann OG; Baccarani M; Kantarjian HM
Eur J Clin Pharmacol; 2013 Apr; 69(4):813-23. PubMed ID: 23052406
[TBL] [Abstract][Full Text] [Related]
10. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
[TBL] [Abstract][Full Text] [Related]
11. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
12. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.
Nicolini FE; Masszi T; Shen Z; Gallagher NJ; Jootar S; Powell BL; Dorlhiac-Llacer PE; Zheng M; Szczudlo T; Turkina A
Leuk Lymphoma; 2012 May; 53(5):907-14. PubMed ID: 22023530
[TBL] [Abstract][Full Text] [Related]
13. Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia.
Chen Y; Yin H; Chen L; Xiong Y; Meng L; Guo J; Wang H; Li W
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e43-e49. PubMed ID: 31902734
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
[TBL] [Abstract][Full Text] [Related]
16. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
[TBL] [Abstract][Full Text] [Related]
17. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
Ishikawa J; Matsumura I; Kawaguchi T; Kuroda J; Nakamae H; Miyamoto T; Matsuoka KI; Shibayama H; Hino M; Hirase C; Kamimura T; Shimose T; Akashi K; Kanakura Y
Int J Hematol; 2018 May; 107(5):535-540. PubMed ID: 29362980
[TBL] [Abstract][Full Text] [Related]
19. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
[TBL] [Abstract][Full Text] [Related]
20. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]